Stryker Corporation (SYK) has entered into a definitive agreement to acquire care.ai, a privately held company specializing in artificial intelligence (AI)-assisted virtual care workflows, smart room technology and ambient intelligence solutions. This acquisition will bolster Stryker's healthcare IT and wirelessly connected medical device portfolio, reinforcing its commitment to providing cutting-edge solutions that address critical challenges in the healthcare sector, such as nursing shortages and staff re ...

Stryker Corporation (SYK) recently announced the launch of its Pangea Plating System, which received FDA clearance in late 2023. Pangea System is likely to provide variable-angle plating for a range of patient demographics, and its portfolio is both extensive and adaptable. With Pangea System on board, Stryker is now the go-to partner for all things trauma-related, including plates, nails, external fixation devices, and more, supported by the company's committed staff and first-rate service. More on the Pan ...

Stryker Today SYK Stryker $322.64 +6.70 (+2.12%) 52-Week Range $249.98 ▼ $361.41 Dividend Yield 0.99% P/E Ratio 36.83 Price Target $373.11 Add to Watchlist Medical and surgical products manufacturer Stryker Co. NYSE: SYK is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive hospital-based emergency services that often occur in the emergency department (ED) or intensive care unit (ICU). These can include trauma care and surgery. Stryker su ...

Stryker Corporation (SYK) recently announced the completion acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast-conserving surgery. As a result of the acquisition, MOLLI's portfolio is likely to boost Stryker's commitment to advancing surgical solutions in breast cancer care. More on the News The MOLLI 2 localization system is made to be reliable and easy to use to facilitate a surgical workflow that is more ...

andresr/E+ via Getty Images Introduction Stryker (NYSE:SYK) is a manufacturer, developer, and distributor of medical products and devices. The company has global operations around the world and has an impact on over 150 million patients a year. With products like MedSurg, Neurotechnology, Orthopaedics and Spine, the company plays a pivotal role in shaping better patient outcomes. Just recently on July 30, Stryker announced its second quarter results for the year. As I've often been on the lookout for compou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-13149 STRYKER CORPORATION (Exact name of registrant as specified in its charter) Michigan 38-1239739 (State of incorporation) (I.R.S. Employer Identification No.) 1941 Stryk ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Stryker (SYK) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-todate performance to find out. The Zacks Consensus Estimate for SYK's full-year earnings has moved 0.1% higher within the past quarter. This signals that analyst sentiment is impr ...

Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com. SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global ...

Financial Data and Key Metrics - The company delivered strong organic growth sales of 9% in Q2 2024, compared to nearly 12% in the same quarter of 2023 [4] - Adjusted EPS for the quarter was $2.81, reflecting 10.6% growth compared to Q2 2023, driven by higher sales and margin expansion [7] - Adjusted gross margin was 64.2%, representing a 30 basis points improvement compared to Q2 2023 [29] - Adjusted operating margin was 24.6% of sales, approximately 30 basis points favorable to Q2 2023 [32] - The company ended Q2 with approximately $2 billion in cash and marketable securities and total debt of $12.2 billion [33] Business Line Performance - MedSurg and Neurotechnology had constant currency sales growth of 9.8% and organic sales growth of 9.7%, with US organic growth at 10.1% and international at 8.2% [28] - Orthopaedics and Spine had constant currency sales growth of 8.9% and organic sales growth of 8%, with US organic growth at 7.3% and international at 9.8% [51] - US trauma and extremities business grew 9.1% organically, driven by strong performances in upper extremities, biologics, and core trauma [20] - US spine business grew 4.4% organically, led by interventional spine performance [20] - Endoscopy had US organic sales growth of 8%, with strong growth in core endoscopy and sports medicine businesses [16] Market Performance - International organic sales growth accelerated to 8.9%, driven by strength in Europe, emerging markets, Australia, New Zealand, and Japan [6] - US organic sales growth was 9%, while international organic sales growth was 8.9% [14] - MedSurg and Neurotechnology had organic sales growth of 8.2% internationally, led by double-digit growth in instruments, neurovascular, and neuro cranial businesses [19] Strategy and Industry Competition - The company remains bullish on its M&A pipeline, with a focus on smaller deals in the first half of 2024 and potentially larger deals in the second half [31] - The company expects sustained growth in its hips and knees businesses, driven by momentum in installations and utilization [11] - The company received FDA clearance for its Spine Guidance 5 Software featuring Copilot, which is expected to enhance patient safety and outcomes [12] - The company completed the acquisition of Artelon and MOLLI Surgical, enhancing its endoscopy portfolio [23] Management Commentary on Operating Environment and Future Outlook - The company raised its full-year 2024 organic sales growth guidance to 9% to 10%, reflecting strong capital backlog, innovative product portfolio, and healthy procedure volumes [24] - Management expects continued strength in procedural demand and capital product demand in the second half of 2024 [8] - The company anticipates a moderately unfavorable impact from foreign exchange rates on full-year sales and EPS, with EPS expected to be negatively impacted by $0.10 to $0.15 [34] Other Important Information - The company repaid $600 million of debt in Q2 2024 [33] - Adjusted R&D spending was 6.5% of sales, approximately 10 basis points higher than Q2 2023 [32] - Adjusted SG&A was 33.1% of sales, consistent with Q2 2023 [32] Q&A Session Summary Question: M&A Pipeline and Margin Targets - The company remains committed to its margin targets of 200 basis points, with 100 basis points expected in 2024 and another 100 basis points in 2025, inclusive of M&A [31] - The company has a strong balance sheet and plans to be active in M&A in the second half of 2024 [36] Question: Margin Expansion Drivers - The company expects more leverage from SG&A in the second half of the year, driven by variable compensation models and cost control measures [49] - The company is confident in achieving 100 basis points of operating margin expansion in 2024 [49] Question: Pricing Trends - The company has seen positive pricing trends, particularly in MedSurg and Neurotech businesses, and expects pricing tailwinds to continue into the second half of 2024 [78] - Pricing initiatives have contributed to a 1.1% favorable impact in Q2 2024 [13] Question: International Growth and Mako Expansion - International growth has been strong, particularly in Mako installations, with significant opportunities in markets like Japan, India, and Europe [81] - The company expects international growth to accelerate in the second half of 2024 and continue to outpace US growth [133] Question: ASC Market Dynamics - The company sees continued growth in the ASC market, with a higher percentage of hips and knees being performed in ASCs [161] - Pricing in the ASC channel is consistent with hospital pricing, and the company expects this trend to continue [151] Question: Supply Chain and Product Launches - The company has resolved supply chain disruptions in neurovascular and expects robust growth in the second half of 2024 [190] - New product launches, such as Pangea and LIFEPAK 35, are expected to drive significant growth in 2025 and beyond [178]

This quarterly report represents an earnings surprise of 0.72%. A quarter ago, it was expected that this medical device maker would post earnings of $2.35 per share when it actually produced earnings of $2.50, delivering a surprise of 6.38%. Stryker, which belongs to the Zacks Medical - Products industry, posted revenues of $5.42 billion for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 0.30%. This compares to year-ago revenues of $5 billion. The company has topped consensus revenu ...